Trimodal Pulsatile Tablet for Once-Daily ADHD Coverage
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing modified-release stimulant dosage forms for ADHD require additional 'booster' doses throughout the day due to fluctuating blood levels, leading to potential crashes or rebound effects, necessitating a need for a single, once-daily oral dosage form that maintains effective therapeutic coverage.
Innovation Solution
A trimodal, precision-timed pulsatile release tablet with three stimulant layers, each releasing at specific times (immediate, delayed, and further delayed) to provide sustained therapeutic effects over 12-16 hours, using a combination of glyceryl behenate and low-substituted hydroxypropyl cellulose as erosion barrier layers.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If a single daily tablet with bimodal release (immediate and delayed) is used, then dosing frequency is reduced and compliance is improved, but therapeutic coverage is insufficient requiring additional booster doses
Solution Approach 1:
The tablet is segmented into three distinct stimulant layers (first, second, and third layers) with different release characteristics. The first layer provides immediate release, the second layer provides delayed release, and the third layer provides extended delayed release, collectively achieving trimodal release patterns that extend therapeutic coverage throughout the day without requiring booster doses
Solution Approach 2:
The patent implements periodic action through trimodal pulsatile release, where the three stimulant layers release the active ingredient at distinct time intervals (immediate, delayed at 3-5 hours, and further delayed at 6-10 hours). This periodic release pattern maintains therapeutic blood levels throughout the day, preventing the crash or rebound effects associated with bimodal release
2Productivity
If stimulant concentration in blood decreases during the latter portions of the day, then dosing frequency can be reduced, but patients experience crash or rebound effects worsening clinical symptoms
Solution Approach 1:
The third stimulant layer is designed to release the active ingredient at a further delayed time period (6-10 hours after administration) specifically to prevent the crash or rebound effects that occur when stimulant concentration decreases during the latter portions of the day. This preliminary action ensures therapeutic coverage is maintained before symptoms would worsen
Solution Approach 2:
The patent changes the release time parameters by introducing a third release phase at 6-10 hours post-administration. This parameter change in the release profile extends the duration of therapeutic action and prevents the decline in blood stimulant concentration that leads to crash or rebound effects, thereby maintaining reliable symptom control
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The tablet achieves precise blood levels of stimulants, reducing dosing frequency, increasing compliance, and minimizing crashes or rebound effects, with reduced treatment emergent adverse events.
Implementation Method 1
By surrounding the second and third stimulant layers with erosion barrier layers, the second and third stimulant pulses can be delayed releases. The delivery of the second stimulant pulse can be delayed until about 3 to about 5 hours following administration of the tablet to a patient. The delivery of the third stimulant pulse can be delayed until about 6 to about 10 hours following oral administration of the tablet to a patient.
Data Source
Figure 1A~1B
Figure 2~3
Figure 4
AI summary
A trimodal, precision-timed pulsatile release tablet that delivers a trimodal (i.e., three pulses) release profile is provided. The tablet includes at least three stimulant layers. By providing a single tablet with multiple stimulant layers, the dosing frequency is decreased, and compliance is expected to increase since precise blood levels of the active pharmaceutical ingredient over a prolonged time period are controlled and achieved.